MedTrace Logo

Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain

NCT05519111 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-10-02

No results posted yet for this study

Summary

A randomized, double blind, study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).

Conditions

Interventions

DRUG

Dronabinol

Dronabinol, an FDA approval oral agent containing synthetic tetrahydrocannabinol (THC)

DRUG

Placebo

placebo equivalent

Sponsors & Collaborators

Principal Investigators

  • Susanna Curtis · MOUNT SINAI HOSPITAL

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-03
Primary Completion
2027-04-01
Completion
2027-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05519111 on ClinicalTrials.gov